Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718343 | 0.80 | LMNA (0.37) | LMNAHTTTDP1POLBKMT2A | |
| SCHEMBL1989669 | 0.78 | TOP1 (0.44) | TOP1ALDH1A1HTTPDE10APOLB | |
| SCHEMBL1990781 | 0.78 | TOP1 (0.44) | TOP1ALDH1A1PDE10A | |
| SCHEMBL1993391 | 0.74 | USP2 (0.39) | ALDH1A1HSD17B10TGFBR1SMN1; SMN2DHODH | |
| SCHEMBL12564510 | 0.74 | CYP1A2 (0.36) | ALDH1A1HSD17B10SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1994712 | 0.73 | MBNL1 (0.40) | LMNAALDH1A1TGFBR1SMN1; SMN2DHODH | |
| SCHEMBL12974145 | 0.72 | NT5E (0.38) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13370780 | 0.71 | PIK3CD (0.55) | — | |
| SCHEMBL28864685 | 0.70 | MET (0.47) | LMNAALDH1A1POLB | |
| SCHEMBL17718398 | 0.70 | AR (0.36) | LMNAALDH1A1HTTHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2513109-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | TOP1 701/4885LMNA 2309/4885ALDH1A1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.